Contemporary Applications and Limitations of Magnetic Resonance Imaging Contrast Materials
Authors:
- 1 January 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 183 (1) , 27-33
Abstract
Improvements in imaging technologies have dramatically increased the ability to accurately diagnose and treat many urological disease processes. As urological patients often have chronic kidney disease, the well characterized nephrotoxicity of contrast induced nephropathy when using iodine based contrast materials has long been a concern. With the development of gadolinium based contrast agents it seemed that the concern regarding nephrotoxicity had been resolved. In 1997 a new disorder, nephrogenic systemic fibrosis, appeared in patients with severe renal failure. Nephrogenic systemic fibrosis is a serious and potentially devastating disorder characterized by progressive thickening and hardening of the skin and other body tissues, and complicated by flexion contractures of the joints. We performed a survey of the available literature on nephrogenic systemic fibrosis and magnetic resonance contrast media. We focused on mechanisms in the development of nephrogenic systemic fibrosis as well as its association with magnetic resonance contrast media, disease treatment and prevention, and its relevance to clinical urology. An association between nephrogenic systemic fibrosis and gadolinium based contrast agents has been reported. Gadolinium is a toxic metal and it must be chelated to be a safe injectable contrast agent. It is now hypothesized that the majority of nephrogenic systemic fibrosis cases present with gadolinium based contrast agent exposure as the triggering factor, although this mechanism has not been elucidated. As gadolinium enhanced magnetic resonance imaging is an important tool in the diagnosis and surveillance of urological diseases, the severe consequences of nephrogenic systemic fibrosis demand that practicing urologists understand and know its history and treatment strategies. This review provides clarification of the gadolinium based contrast agent characteristics, tissue interactions that lead to the development of nephrogenic systemic fibrosis, prevention possibilities and available treatment options.Keywords
This publication has 42 references indexed in Scilit:
- Risk for Nephrogenic Systemic Fibrosis with Gadoteridol (ProHance) in Patients Who Are on Long-Term HemodialysisClinical Journal of the American Society of Nephrology, 2008
- NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium‐Based Contrast Agents?Seminars in Dialysis, 2008
- Comparison of a Tartaric Acid Derived Polymeric MRI Contrast Agent to a Small Molecule Model ChelateBioconjugate Chemistry, 2007
- Comparison of the Usefulness of Gadodiamide and Iodine Mixture Versus Iodinated Contrast Alone for Prevention of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease Undergoing Coronary AngiographyThe American Journal of Cardiology, 2007
- Toxicological assessment of gadolinium release from contrast mediaExperimental and Toxicologic Pathology, 2007
- Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a reviewFundamental & Clinical Pharmacology, 2006
- A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patientsNephrology Dialysis Transplantation, 2006
- Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrology Dialysis Transplantation, 2006
- Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) Retention in Human Bone Tissue by Inductively Coupled Plasma Atomic Emission SpectroscopyInvestigative Radiology, 2004
- Scleromyxoedema-like cutaneous diseases in renal-dialysis patientsThe Lancet, 2000